Intensive Blood Pressure Therapy Fails to Significantly Cut Cardiovascular Events in Type 2 Diabetes

A large trial found that intensive blood pressure lowering below 120 mm Hg did not significantly reduce major cardiovascular events in adults with Type 2 diabetes compared to standard treatment, though a modest benefit may still exist, suggesting that blood pressure targets should be individualized.

Chicago Metrowire Staff
••Healthcare
Intensive Blood Pressure Therapy Fails to Significantly Cut Cardiovascular Events in Type 2 Diabetes

For adults with Type 2 diabetes and high blood pressure, pushing systolic blood pressure below 120 mm Hg with medication did not significantly reduce the incidence of cardiovascular death, stroke, heart attack or other cardiovascular events compared to a standard target of less than 140 mm Hg, according to late-breaking research presented at the American Heart Association’s Scientific Sessions 2026 in Chicago. The findings, from the OPTIMAL-DIABETES trial, simultaneously published in the New England Journal of Medicine, carry important implications for how aggressively clinicians should treat high blood pressure in this high-risk population.

The trial enrolled more than 9,000 adults aged 50 and older with Type 2 diabetes and elevated systolic blood pressure between 130 and 180 mm Hg at 33 sites in Brazil. Participants were randomly assigned to intensive therapy targeting systolic pressure below 120 mm Hg or standard treatment targeting below 140 mm Hg. Over a median follow-up of four years, the intensive group experienced a 10% lower relative risk of major cardiovascular events—6.0% versus 6.7% in the standard group—but the difference was not statistically significant. However, kidney-related events were about 55% higher in the intensive group (5.7% vs. 3.7%), primarily declines in kidney function, though end-stage renal disease rates were similar between groups and serious adverse events did not differ.

“These findings should not be interpreted as evidence that more intensive blood pressure lowering is ineffective for people with Type 2 diabetes,” said Otavio Berwanger, M.D., Ph.D., chair of the trial’s steering committee and executive director at The George Institute for Global Health – Imperial College London. He noted that any cardiovascular benefit may be smaller than in people without diabetes, and even a large trial like OPTIMAL-DIABETES may not have been able to definitively detect a modest treatment effect. The results underscore that a universal target below 120 mm Hg is not appropriate for all patients with Type 2 diabetes; instead, treatment decisions should balance potential cardiovascular benefits, kidney effects, treatment burden and patient preferences.

The study’s context is critical. The American Heart Association/American College of Cardiology’s 2025 Joint Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults identifies high blood pressure as the leading preventable risk factor for cardiovascular disease, including heart attack, stroke and heart failure, as well as kidney disease and cognitive decline. The guideline recommends a general target of less than 130/80 mm Hg and encourages reaching below 120 mm Hg for those at increased cardiovascular risk. The OPTIMAL-DIABETES results suggest that for adults with Type 2 diabetes, the balance of benefits and harms may differ, particularly regarding kidney outcomes.

“While this trial did not find a statistically significant reduction in major cardiovascular events, more intensive blood pressure treatment may still have modest yet meaningful health benefits for adults with Type 2 diabetes,” said lead author Karla Santo, M.D., Ph.D., of the Academic Research Organization of Einstein Hospital Israelita in São Paulo, Brazil. The trial’s open-label design and its conduct solely in Brazil limit generalizability, but the findings add crucial evidence to the ongoing debate over optimal blood pressure targets. They highlight the need to consider the totality of evidence rather than any single trial when defining targets for patients with Type 2 diabetes, and they reinforce that individualized care remains paramount.

Blockchain Registration

QR Code for Blockchain Registration